{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79"}]}],"title":"PD-L1 CPS <1%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"172"}]}],"title":"PD-L1 CPS ≥1% to <10%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"110"}]}],"title":"PD-L1 CPS ≥10%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"}],"units":"Participants"}],"description":"PD-L1 expression status was determined as the percent of disease tumor cells, from newly obtained tumor biopsies, demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. The assay uses a Combined Positive Score (CPS) as a measure of PD-L1 positivity. The CPS is calculated as the number of PD-L1-positive cells divided by the number of viable tumor cells analyzed multiplied by 100. A CPS of \\<1% = negative; ≥1% = positive; and ≥10% = strongly positive. Per protocol, only data generated during the initial course of treatment contributed to the analysis.","groups":[{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 2 years. Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to an additional year.","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one dose of study treatment during the initial course of treatment","reportingStatus":"POSTED","timeFrame":"Day 1","title":"Programmed Cell Death Ligand 1 (PD-L1) Expression Status","type":"SECONDARY","unitOfMeasure":"Participants"}